© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 09, 2022
Scott Tykodi, MD, PhD, discusses using DFS as a primary end point in trials, as well as the usage of biomarkers.
Moshe Ornstein, MD, MA, discusses his approach to adjuvant therapy while treating patients with advanced clear cell RCC.
Nizar Tannir, MD, describes the data, criteria, and end points of the KEYNOTE-564 trial.
October 31, 2022
Dr Nizar Tannir describes data presented at ASCO 2022 from EVEREST investigating everolimus vs placebo for patients with high-risk disease.
Experts discuss the use of pembrolizumab as an adjuvant therapy in advanced clear cell RCC.
October 24, 2022
Dr Scott Tykodi explains the scenarios in which he would switch a patient to another regimen without dose reduction first.